GT20029. Kintor Pharma’s Product
    Research/Science 11/26/2022

    At a glance
    In this general discussion post, the primary subjects mentioned are
    💧 GT20029 (topical)
    💉 HMI-115 (injection)
    💊 Finasteride (oral)
    💧 Pyrilutamide (topical)
    the tone is 😐 neutral.

    Other terms

    The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
    View this post in the Community →

    Similar Community Posts Join

    5 / 233 results

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

      in Research/Science  124 upvotes 1 year ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

      community Kintor’s GT20029 Phase 1 success

      in Update  75 upvotes 2 years ago
      Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

    Related Research

    5 / 5 results